Cited In for PMID: 39739856

Your saved search

Your RSS Feed

Year	Number of Results
2024	1
2025	3
2026	0

Results by year

Page 1

Treatment of pembrolizumab-induced bullous pemphigoid with dupilumab: A case report and review of the literature.

Barghi A, Noveir SD, Mainwaring W, Milani-Nejad N, Bernet L. Barghi A, et al. Int J Dermatol. 2025 Aug;64(8):1474-1476. doi: 10.1111/ijd.17626. Epub 2024 Dec 30. Int J Dermatol. 2025. PMID: 39739856 No abstract available.

Case Report: Dupilumab therapy for immune checkpoint inhibitor-induced bullous pemphigoid enables dual immunotherapy initiation in progressive malignant melanoma.

Grüninger J, Lehr S, Meiss F, Rafei D, Schauer F. Grüninger J, et al. Front Oncol. 2025 Sep 25;15:1613552. doi: 10.3389/fonc.2025.1613552. eCollection 2025. Front Oncol. 2025. PMID: 41079106 Free PMC article.

Dupilumab for the Treatment of Cutaneous Immune-Related Adverse Events: A Systematic Review.

Koumprentziotis IA, Niforou A, Tsimpidakis A, Nikolaou C, Stratigos A, Nikolaou V. Koumprentziotis IA, et al. Int J Dermatol. 2025 Oct;64(10):1825-1832. doi: 10.1111/ijd.17850. Epub 2025 May 15. Int J Dermatol. 2025. PMID: 40375468 Free PMC article.

Page of 1

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Cited In for PMID: 39739856

3 results

Results by year